Past Tuesday Talks — How Life Science Companies Use AI to Target Investors

Tuesday, September 5, 2023

Presented by Seema Kumar, CEO, Cure

On this week’s Tuesday Talks, Cure CEO Seema Kumar speaks with Joe Wilson, Managing Partner at Undeterred Capital in Los Angeles. Joe will share what investors are looking for in new life science companies now—and just how hot AI in drug discovery is with funders. Plus, hear why he dropped out of MIT to start an FDA-grade robotics facility.

Watch Tuesday Talks, Live on LinkedIn September 5, 4 p.m. EDT

When: Tuesday, September 5, 4:00 p.m.
Where: LIVE on LinkedIn Live

Topic: A fireside chat with Joe Wilson, Founder and Managing Partner at Undeterred Capital in Los Angeles, on AI in drug discovery and its impact on funders.

Speakers: Joe Wilson, Founder and Managing Partner at Undeterred Capital. In conversation with Seema Kumar.

Featured Speakers

About Joe Wilson

Joe Wilson is the Founder and Managing Partner of Undeterred Capital, where he leads all investment and strategic efforts at the firm. Undeterred Capital is an early stage venture capital firm, investing exclusively in bioscience and deep tech companies at the pre-seed and seed stages. Undeterred has a portfolio of nearly 20 companies collectively valued at over $1 billion. Investments to date include AI for drug discovery and formulation, carbon-negative food production enabled by computational biology, and diagnostics for early detection of ovarian cancer, among others. Joe was previously the co-founder and COO of Multiply Labs, a pharmaceutical robotics company that was spun out of MIT in 2016. Multiply Labs has raised over $25M in venture funding to date, from top venture capital firms including Y Combinator, Lux Capital, Josh Buckley, and Casdin Capital, among others. Joe was subsequently a venture partner at MarsBio, an early-stage biotech fund.

About Seema Kumar

Seema joined Cure Experience in 2022 as the Chief Executive Officer. Prior to Cure, Ms. Kumar spent nearly 20 years at Johnson & Johnson in senior leadership roles, including most recently as the Global Head, Office of Innovation, Global Health and Scientific Engagement, and served on J&J’s Innovation Strategy, Public health leadership and the COVID-19 vaccine steering committee, where she led the company’s external affairs efforts and public education program on COVID and vaccine literacy. Before her tenure at J&J, Ms. Kumar was the Chief of Staff to Dr. Eric Lander and the Chief Communications Officer at the Whitehead Institute/Massachusetts Institute of Technology Center for Genome Research where she played a leadership role in the Human Genome Project. She also has held leadership positions at the U.S. National Institutes of Allergy and Infectious Diseases (NIAID), the National Institutes of Health, and Johns Hopkins School of Medicine. Ms. Kumar holds an M.S. in Science Journalism and Communications from the University of Maryland.